Tatva Chintan Pharma Chem Ltd. News and Updates

Name: Latest research reports of Tatva Chintan Pharma Chem Ltd. authored by KRChoksey and published by - Trendlyne research reports.
Item: Tatva Chintan Pharma Chem Ltd.
Rating: 1
Author: KRChoksey

Keep track of all breaking news on Tatva Chintan Pharma Chem Ltd. from all sources in a single place.

Tatva Chintan Pharma Chem Ltd.

30 Jan 2025

738.00

-0.61%

Tatva Chintan Pharma Chem Q3 Results 2025 on 30 Jan, 2025: profit falls by 95.94% YOY, profit at 0.14 crore and revenue at 85.9 crore

livemint

Tatva Chintan Pharma Chem Q3 Results 2025 on 30 Jan, 2025: Revenue increased by 2.01% YoY & profit decreased by 95.94% YoY, profit at 0.14 crore and revenue at 85.9 crore

Tatva Chintan Pharma Chem Ltd. is trading above its 50 day SMA of 702.7

Tatva Chintan Pharma Chem Ltd.

30 Jan 2025

738.00

-0.61%

Outlook remains uncertain with lack of visibility in the key SDA segment

Sell: Tatva Chintan Pharma Chem ...

Target

KRChoksey

TATVA revenue missed our estimates due to significant decline in SDA segment. EBITDA beat our estimates due to lower-than-expected cost of goods sold and operating expenses. However, Adj PAT missed our estimates significantly due to higher-than-expected depreciation, lower than expected other income.

Tatva Chintan Pharma.. has an average target of 1130.50 from 2 brokers.

Tatva Chintan Pharma Chem Ltd.

28 Jan 2025

738.00

-0.61%

to see Rapid results content

Tatva Chintan Pharma Chem Ltd.

28 Oct 2024

738.00

-0.61%

Multiple headwinds across demand and supply sides persist

Sell: Tatva Chintan Pharma Chem ...

Recommendation Target

KRChoksey

Tatva Chintan Pharma Chem’s revenue and profitability missed our estimates significantly due to muted demand across business segments, lower price realization, and an increase in fixed costs.
We believe short term pain will persist as Q3FY25E is expected to have similar performance; However, mid-term may improve gradually with a pick-up in global demand and commercialization of new products.

Tatva Chintan Pharma Chem Ltd. is trading below its 100 day SMA of 779.1

Tatva Chintan Pharma Chem Ltd.

25 Oct 2024

738.00

-0.61%

Tatva Chintan Pharma Chem Results Earnings Call for Q2FY25

Conference Call with Tatva Chintan Pharma Chem Management and Analysts on Q2FY25 Performance and Outlook. Listen to the full earnings transcript.

Tatva Chintan Pharma Chem Ltd.

25 Oct 2024

738.00

-0.61%

to see Rapid results content

Tatva Chintan Pharma Chem Ltd.

30 Jul 2024

738.00

-0.61%

Fall in price realization impacted topline and profitability

Hold: Tatva Chintan Pharma Chem ...

Target

KRChoksey

Tatva Chintan Pharma Chem’s revenue missed our estimates (-32.7%) due to a steep decline in price realization. EBITDA missed our estimate (-58.1%) due to better-than-expected operating expenses.

Tatva Chintan Pharma Chem Ltd. has lost -20.93% in the last 6 Months

Tatva Chintan Pharma Chem Ltd.

25 Jul 2024

738.00

-0.61%

Tatva Chintan Pharma Q1 Results Review - Yet Another Cut In FY25 Guidance: Nirmal Bang

NDTV Profit

Demand and pricing recovery and timely commercialisation of projects are key monitorables, in brokerages' view.

Tatva Chintan Pharma Chem Ltd. is trading below its 100 day SMA of 779.1

Tatva Chintan Pharma Chem Ltd.

25 Jul 2024

738.00

-0.61%

Margins impacted by high-cost inventory

Buy: Tatva Chintan Pharma Chem ...

Target

ICICI Securities Limited

Tatva Chintan Pharma Chem’s (TATVA) revenue grew 7.3% QoQ, but gross profit margin collapsed to just 45.9% (vs 57.8% in Q4FY24) due to high-cost inventory, particularly in SDA, where it had to take 15-20% price.